All In Biotech

Drug Trial Radar · NCT07073014

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

140

Planned (sponsor's estimate)

Start

Jun 20, 2025

Primary completion

Oct 2044

Study completion Oct 2044

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH

Conditions

  • Hypochondroplasia

Interventions

  • VosoritideDrug

    Open-label administration of vosoritide using weight-band dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)Time frame: Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males

Locations

30 sites in 9 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital - Thomas Campus

    Phoenix, Arizona

  • Benioff Children's Hospital - Oakland

    Oakland, California

  • Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children)

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • University of Minnesota Masonic Children's Hospital

    Minneapolis, Minnesota

  • University of Missouri

    Columbia, Missouri

  • Cook Children's Endocrinology

    Fort Worth, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Murdoch Children's Research Institute of The Royal Children's Hospital

    Parkville, Victoria, Australia

  • University of Alberta Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • SickKids - The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, Canada

  • Hospices Civils de Lyon - Hopital Femme Mere Enfant

    Lyon, France

  • Hopital de la Timone

    Marseille, France

  • Hopital Necker-Enfants Malade

    Paris, France

  • CHU de Toulouse

    Toulouse, France

  • Uniklinik Koln

    Cologne, Germany

  • Univeristatskinderklinik Magdeburg

    Magdeburg, Germany

  • Universitätsklinikum des Saarlandes

    Homburg, Saarland, Germany

  • Instituto Giannina Gaslini

    Genoa, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Italy

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy

  • Osaka University Hosptial

    Osaka, Japan

  • Tokushima University Hospital

    Tokushima, Japan

  • Institute of Science Tokyo Hospital

    Tokyo, Japan

  • Tottori University Hospital

    Tottori, Japan

  • Hospital MiKS - Unidad de Cirugía Artroscópica

    Vitoria-Gasteiz, Spain

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.